Torsdag 19 November | 08:13:11 Europe / Stockholm
Est. tid*
2027-05-11 N/A Årsstämma
2027-02-11 08:00 Bokslutskommuniké 2026
2026-11-11 - Kvartalsrapport 2026-Q3
2026-08-20 - Kvartalsrapport 2026-Q2
2026-05-11 - X-dag ordinarie utdelning IMMU 0.00 SEK
2026-05-08 - Årsstämma
2026-05-08 - Kvartalsrapport 2026-Q1
2026-02-11 - Bokslutskommuniké 2025
2025-12-16 - Extra Bolagsstämma 2025
2025-11-13 - Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning IMMU 0.00 SEK
2025-05-06 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-06-03 - Split IMMU 20:1
2024-05-20 - X-dag ordinarie utdelning IMMU 0.00 SEK
2024-05-17 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-12-13 - Extra Bolagsstämma 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-15 - X-dag ordinarie utdelning IMMU 0.00 SEK
2023-05-12 - Årsstämma
2023-05-12 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-18 - Extra Bolagsstämma 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning IMMU 0.00 SEK
2022-05-10 - Årsstämma
2022-05-10 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-05 - X-dag ordinarie utdelning IMMU 0.00 SEK
2021-05-04 - Årsstämma
2021-05-04 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2021-01-22 - Extra Bolagsstämma 2021
2020-12-18 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-04-29 - X-dag ordinarie utdelning IMMU 0.00 SEK
2020-04-28 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-18 - Bokslutskommuniké 2019
2019-11-06 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-04-26 - X-dag ordinarie utdelning IMMU 0.00 SEK
2019-04-25 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-08-17 - Kvartalsrapport 2018-Q2
2018-05-04 - Kvartalsrapport 2018-Q1
2018-04-26 - X-dag ordinarie utdelning IMMU 0.00 SEK
2018-04-25 - Årsstämma
2018-02-16 - Bokslutskommuniké 2017
2017-12-04 - Extra Bolagsstämma 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-18 - Kvartalsrapport 2017-Q2
2017-05-19 - Kvartalsrapport 2017-Q1
2017-04-27 - X-dag ordinarie utdelning IMMU 0.00 SEK
2017-04-26 - Årsstämma
2017-02-17 - Bokslutskommuniké 2016
2016-05-20 - Kvartalsrapport 2016-Q3
2016-02-19 - Kvartalsrapport 2016-Q2
2015-12-03 - Årsstämma
2015-09-18 - Bokslutskommuniké 2015
2015-05-21 - Kvartalsrapport 2015-Q3
2015-02-20 - Kvartalsrapport 2015-Q2
2014-12-04 - X-dag ordinarie utdelning IMMU 0.00 SEK
2014-12-03 - Årsstämma
2014-11-18 - Kvartalsrapport 2015-Q1
2014-09-17 - Bokslutskommuniké 2014
2014-05-07 - Kvartalsrapport 2014-Q3
2014-02-18 - Kvartalsrapport 2014-Q2
2013-12-04 - X-dag ordinarie utdelning IMMU 0.00 SEK
2013-12-03 - Årsstämma
2013-12-03 - Kvartalsrapport 2014-Q1
2013-09-10 - Bokslutskommuniké 2013
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Mendus är verksamt inom medicinteknik. Bolaget producerar terapeutiska vacciner som används inom området för onkologi. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet med fokus på behandling av allvarliga tumörer. Exempel på sjukdomar som produkterna används mot innefattar njur- och levercancer. Störst verksamhet återfinns inom den nordiska marknaden. Mendus grundades år 2002 och har sitt huvudkontor i Stockholm.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Mendus and NorthX Biologics expand collaboration to include production of memory NK cell therapies

2026-11-10 08:00:00
  • Mendus and NorthX Biologics expand their collaboration to establish manufacturing of memory NK cells for therapeutic purposes, alongside the ongoing large-scale production of Mendus’ lead product vididencel.
  • The project, selected through Vinnova's competitive Life Science Infrastructure program, has been awarded approximately SEK 1 million to support establishment of the manufacturing platform.

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on transforming immunotherapies targeting myeloid blood cancers, today announced that it has been awarded a SEK 977,300 grant by Vinnova, Sweden's innovation agency, to establish production of memory NK cell-based therapies, together with its manufacturing partner NorthX Biologics.

The grant was awarded through Vinnova's competitive "Utilize Infrastructures for Innovation in Life Science" program following an evaluation by an independent panel of external experts. In its assessment, Vinnova highlighted the project's "high potential to strengthen national capacity within cell therapy and create strategically important infrastructure for future commercialization," and noted the feasibility of the project plan, the strength of the collaborations, and the expertise of the project team.

"We are pleased that Vinnova has recognized both the strategic importance and potential impact of this initiative," said Erik Manting, Chief Executive Officer of Mendus. "Establishing manufacturing of donor-derived memory NK cells may create future opportunities to address unmet needs in AML, particularly in the post-transplant setting where we have not positioned vididencel. We are excited to take our potential best-in-class NK cell program to the next phase of development."

In 2023, Mendus and NorthX Biologics established a large-scale manufacturing alliance for vididencel, Mendus’ lead product for the treatment of myeloid blood cancers. Mendus and NorthX Biologics will now expand their collaboration to produce memory NK cells from healthy donor material, using Mendus’ proprietary DCOne technology. Donor-derived memory NK cells are being explored for potential therapeutic application in AML patients following stem cell transplantation. While separate from the Company's lead program vididencel, the project further expands Mendus' immunotherapy approaches targeting AML.

About NK memory cells
Natural killer (NK) cells are immune cells that play an important role in identifying and eliminating cancer cells. A subgroup called memory, or adaptive NK cells have demonstrated enhanced and sustained anti-tumor activity and are being investigated as a potential cell therapy approach in hematological malignancies, including acute myeloid leukemia (AML). Their presence following allogeneic stem cell transplantation has been associated with reduced relapse, providing rationale to develop memory NK cell-based therapies as a post-transplant treatment to improve disease-free survival.

About NorthX Biologics
NorthX Biologics is a Swedish biopharmaceutical contract development and manufacturing organization (CDMO) and industrial infrastructure provider specializing in advanced biologics and cell and gene therapies. In 2021, the company was designated by the Swedish government as a national competence center for advanced biologics and gene therapies.

About Vinnova
Vinnova is Sweden's innovation agency. Its mission is to strengthen Sweden's innovation capacity and contribute to sustainable growth by supporting collaboration between companies, academia, public organizations and other stakeholders. Vinnova invests approximately SEK 3.5 billion annually in research and innovation initiatives.